{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:41:07Z","timestamp":1791848467969,"version":"4.3.4"},"reference-count":107,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE11-0003-01"],"award-info":[{"award-number":["ANR-22-CE11-0003-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Smallpox was a highly contagious disease caused by the variola virus. The disease affected millions of people over thousands of years and variola virus ranked as one of the deadliest viruses in human history. The complete eradication of smallpox in 1980, a major triumph in medicine, was achieved through a global vaccination campaign using a less virulent poxvirus, vaccinia virus. Despite this success, the herd immunity established by this campaign has significantly waned, and concerns are rising about the potential reintroduction of variola virus as a biological weapon or the emergence of zoonotic poxviruses. These fears were further fueled in 2022 by a global outbreak of monkeypox virus (mpox), which spread to over 100 countries, thereby boosting interest in developing new vaccines using molecular approaches. However, poxviruses are complex and creating modern vaccines against them is challenging. This review focuses on the structural biology of the six major neutralization determinants on poxviruses (D8, H3, A27, L1, B5, and A33), the localization of epitopes targeted by neutralizing antibodies, and their application in the development of subunit vaccines.<\/jats:p>","DOI":"10.3390\/v15122396","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T08:47:26Z","timestamp":1702025246000},"page":"2396","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neutralization Determinants on Poxviruses"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8319-0922","authenticated-orcid":false,"given":"Vernuccio","family":"Riccardo","sequence":"first","affiliation":[{"name":"Structural Biology of Infectious Diseases Unit, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-5270","authenticated-orcid":false,"given":"Guardado-Calvo","family":"Pablo","sequence":"additional","affiliation":[{"name":"Structural Biology of Infectious Diseases Unit, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1086\/381976","article-title":"Looking back at smallpox","volume":"38","author":"Bray","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4997\/JRCPE.2015.217","article-title":"An examination of John Fewster\u2019s role in the discovery of smallpox vaccination","volume":"45","author":"Thurston","year":"2015","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: Targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yang, Z., Gray, M., and Winter, L. (2021). Why do poxviruses still matter?. Cell Biosci., 11.","DOI":"10.1186\/s13578-021-00610-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3121\/cmr.1.2.87","article-title":"Smallpox vaccine: The good, the bad, and the ugly","volume":"1","author":"Belongia","year":"2003","journal-title":"Clin. Med. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijid.2004.09.002","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2014A second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int. J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","article-title":"Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals","volume":"29","author":"Zaeck","year":"2023","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hazra, A., Zucker, J., Bell, E., Flores, J., Gordon, L., Mitja, O., Suner, C., Lemaignen, A., Jamard, S., and Nozza, S. (2023). Mpox in people with past infection or a complete vaccination course: A global case series. Lancet Infect. Dis.","DOI":"10.2139\/ssrn.4491622"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1016\/j.vaccine.2020.07.018","article-title":"Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus","volume":"38","author":"Xiao","year":"2020","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Golden, J.W., Josleyn, M., Mucker, E.M., Hung, C.F., Loudon, P.T., Wu, T.C., and Hooper, J.W. (2012). Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042353"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1038\/s41467-023-41628-5","article-title":"mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge","volume":"14","author":"Hou","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","article-title":"Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus","volume":"8","author":"Sang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2192815","DOI":"10.1080\/22221751.2023.2192815","article-title":"Rational development of multicomponent mRNA vaccine candidates against mpox","volume":"12","author":"Zhang","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"Perdiguero","year":"2015","journal-title":"Viruses"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1073\/pnas.0409825102","article-title":"Cryo-electron tomography of vaccinia virus","volume":"102","author":"Cyrklaff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246(R) for Treatment of Poxvirus Infections","volume":"2","author":"Jordan","year":"2010","journal-title":"Viruses"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1073\/pnas.0601025103","article-title":"Ligand-induced and nonfusogenic dissolution of a viral membrane","volume":"103","author":"Law","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.coi.2004.05.013","article-title":"Immunological memory to viral infection","volume":"16","author":"Slifka","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Golding","year":"2005","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1128\/JVI.00116-06","article-title":"Obligatory requirement for antibody in recovery from a primary poxvirus infection","volume":"80","author":"Chaudhri","year":"2006","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.4049\/jimmunol.172.10.6265","article-title":"Cellular and humoral immunity against vaccinia virus infection of mice","volume":"172","author":"Xu","year":"2004","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/423851","article-title":"Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus","volume":"190","author":"Orr","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1542\/peds.26.2.176","article-title":"Studies smallpox and complications of smallpox vaccination","volume":"26","author":"Kempe","year":"1960","journal-title":"Pediatrics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.0408782102","article-title":"Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery","volume":"102","author":"Davies","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Noy-Porat, T., Tamir, H., Alcalay, R., Rosenfeld, R., Epstein, E., Cherry, L., Achdout, H., Erez, N., Politi, B., and Yahalom-Ronen, Y. (2023). Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.01598-23"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/376557","article-title":"Development of a novel vaccinia-neutralization assay based on reporter-gene expression","volume":"188","author":"Manischewitz","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_33","first-page":"406","article-title":"Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus","volume":"11","author":"Cosma","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10684","DOI":"10.1128\/JVI.77.19.10684-10688.2003","article-title":"Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein","volume":"77","author":"Earl","year":"2003","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","article-title":"Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections","volume":"167","author":"Gilchuk","year":"2016","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R","volume":"79","author":"Whitbeck","year":"2005","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1099\/0022-1317-83-1-209","article-title":"Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: Role of the A33R protein in antibody-resistant spread","volume":"83","author":"Law","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1128\/JVI.74.7.3353-3365.2000","article-title":"Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo","volume":"74","author":"Lin","year":"2000","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1128\/jvi.62.10.3772-3778.1988","article-title":"Vaccinia virus gene D8 encodes a virion transmembrane protein","volume":"62","author":"Niles","year":"1988","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/jvi.56.2.482-488.1985","article-title":"Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus","volume":"56","author":"Rodriguez","year":"1985","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.virol.2010.05.025","article-title":"The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein","volume":"405","author":"Shinoda","year":"2010","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/viro.2001.1131","article-title":"The A17L gene product of vaccinia virus is exposed on the surface of IMV","volume":"290","author":"Wallengren","year":"2001","journal-title":"Virology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0042-6822(92)90535-W","article-title":"A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope","volume":"188","author":"Engelstad","year":"1992","journal-title":"Virology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3851\/IMP1573","article-title":"Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model","volume":"15","author":"McCausland","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/jvi.70.6.3753-3762.1996","article-title":"Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene","volume":"70","author":"Roper","year":"1996","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1743-422X-10-229","article-title":"Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response","volume":"10","author":"Paran","year":"2013","journal-title":"Virol. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1128\/JVI.00906-07","article-title":"Characterization of chimpanzee\/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model","volume":"81","author":"Chen","year":"2007","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"eadg1855","DOI":"10.1126\/scitranslmed.adg1855","article-title":"Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody","volume":"15","author":"Mittler","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"eabl5399","DOI":"10.1126\/scitranslmed.abl5399","article-title":"Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses","volume":"14","author":"Mittler","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eadg3540","DOI":"10.1126\/scitranslmed.adg3540","article-title":"An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge","volume":"15","author":"Freyn","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.coi.2009.04.004","article-title":"The immunology of smallpox vaccines","volume":"21","author":"Kennedy","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Meyer, H., Ehmann, R., and Smith, G.L. (2020). Smallpox in the Post-Eradication Era. Viruses, 12.","DOI":"10.3390\/v12020138"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/jvi.66.1.183-189.1992","article-title":"Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells","volume":"66","author":"Rodriguez","year":"1992","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Matho, M.H., de Val, N., Miller, G.M., Brown, J., Schlossman, A., Meng, X., Crotty, S., Peters, B., Xiang, Y., and Hsieh-Wilson, L.C. (2014). Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-E. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004495"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.virol.2010.10.019","article-title":"Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus","volume":"409","author":"Meng","year":"2011","journal-title":"Virology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1074\/jbc.M117.814541","article-title":"Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8","volume":"293","author":"Matho","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8050","DOI":"10.1128\/JVI.00836-12","article-title":"Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5","volume":"86","author":"Matho","year":"2012","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1128\/JVI.02878-15","article-title":"Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox","volume":"90","author":"Kaever","year":"2016","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1128\/JVI.01491-14","article-title":"Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein","volume":"88","author":"Kaever","year":"2014","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Matho, M.H., Schlossman, A., Meng, X., Benhnia, M.R., Kaever, T., Buller, M., Doronin, K., Parker, S., Peters, B., and Crotty, S. (2015). Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005148"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1128\/JVI.74.16.7518-7528.2000","article-title":"Effects of deletion or stringent repression of the H3L envelope gene on vaccinia virus replication","volume":"74","author":"Wolffe","year":"2000","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1128\/JVI.02933-15","article-title":"The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose","volume":"90","author":"Singh","year":"2016","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Mirzakhanyan, Y., and Gershon, P. (2019). The Vaccinia virion: Filling the gap between atomic and ultrastructure. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007508"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/pmic.200600926","article-title":"Proteome-wide analysis of the serological response to vaccinia and smallpox","volume":"7","author":"Davies","year":"2007","journal-title":"Proteomics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/JVI.02089-12","article-title":"Humoral immunity to smallpox vaccines and monkeypox virus challenge: Proteomic assessment and clinical correlations","volume":"87","author":"Townsend","year":"2013","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine","volume":"82","author":"Benhnia","year":"2008","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chang, T.H., Chang, S.J., Hsieh, F.L., Ko, T.P., Lin, C.T., Ho, M.R., Wang, I., Hsu, S.T., Guo, R.T., and Chang, W. (2013). Crystal structure of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003563"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/jvi.61.2.395-404.1987","article-title":"A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers","volume":"61","author":"Rodriguez","year":"1987","journal-title":"J. Virol."},{"key":"ref_76","first-page":"149","article-title":"Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex","volume":"10","author":"Kochan","year":"2008","journal-title":"Cell Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","article-title":"Mpox vaccine and infection-driven human immune signatures: An immunological analysis of an observational study","volume":"23","author":"Cohn","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1128\/JVI.00568-08","article-title":"Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge","volume":"82","author":"Fogg","year":"2008","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e0085221","DOI":"10.1128\/JVI.00852-21","article-title":"Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells","volume":"95","author":"Schin","year":"2021","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/viro.1994.1405","article-title":"Identification of a vaccinia virus penetration protein","volume":"202","author":"Ichihashi","year":"1994","journal-title":"Virology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.virol.2008.12.019","article-title":"Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans","volume":"385","author":"Foo","year":"2009","journal-title":"Virology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1128\/jvi.68.10.6401-6410.1994","article-title":"Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly","volume":"68","author":"Ravanello","year":"1994","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0501103102","article-title":"The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies","volume":"102","author":"Su","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Priyamvada, L., Kallemeijn, W.W., Faronato, M., Wilkins, K., Goldsmith, C.S., Cotter, C.A., Ojeda, S., Solari, R., Moss, B., and Tate, E.W. (2022). Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry. PLoS Pathog., 18.","DOI":"10.1101\/2022.06.13.495866"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/JVI.06703-11","article-title":"The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry","volume":"86","author":"Foo","year":"2012","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1038\/s41467-023-41587-x","article-title":"Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals","volume":"14","author":"Otter","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.virol.2007.06.042","article-title":"Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein","volume":"368","author":"Su","year":"2007","journal-title":"Virology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1128\/JVI.00374-07","article-title":"Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6","volume":"81","author":"Xiao","year":"2007","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/erv.10.5","article-title":"Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge","volume":"9","author":"Paran","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02155-19","article-title":"Vaccinia Virus Glycoproteins A33, A34, and B5 Form a Complex for Efficient Endoplasmic Reticulum to trans-Golgi Network Transport","volume":"94","author":"Monticelli","year":"2020","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2010.03.017","article-title":"There is an A33-dependent mechanism for the incorporation of B5-GFP into vaccinia virus extracellular enveloped virions","volume":"402","author":"Chan","year":"2010","journal-title":"Virology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/JVI.72.5.4192-4204.1998","article-title":"The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus","volume":"72","author":"Roper","year":"1998","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11637","DOI":"10.1128\/JVI.76.22.11637-11644.2002","article-title":"Identification of second-site mutations that enhance release and spread of vaccinia virus","volume":"76","author":"Katz","year":"2002","journal-title":"J. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/JVI.02247-09","article-title":"The structure of the poxvirus A33 protein reveals a dimer of unique C-type lectin-like domains","volume":"84","author":"Su","year":"2010","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.adg8116","article-title":"APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016","volume":"382","author":"Neher","year":"2023","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.15585\/mmwr.mm7149a4","article-title":"Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak\u2014United States, May 22\u2013October 21, 2022","volume":"71","author":"Duffy","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1016\/j.vaccine.2022.10.078","article-title":"Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo","volume":"40","author":"Priyamvada","year":"2022","journal-title":"Vaccine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","article-title":"Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges","volume":"25","author":"Fogg","year":"2007","journal-title":"Vaccine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.virol.2007.01.001","article-title":"Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge","volume":"362","author":"Thornburg","year":"2007","journal-title":"Virology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge","volume":"28","author":"Buchman","year":"2010","journal-title":"Vaccine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.vaccine.2009.09.133","article-title":"Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates","volume":"28","author":"Hooper","year":"2009","journal-title":"Vaccine"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2396\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:41Z","timestamp":1760132141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":107,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["v15122396"],"URL":"https:\/\/doi.org\/10.3390\/v15122396","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}